title: Prolonged inhibition of cholesterol synthesis explains the efficacy of atorvastatin.
abstract: HMG-CoA reductase inhibitors or statins are effective in both the primary and secondary prevention of coronary heart disease, the extent of benefit being proportional to the reduction in low density lipoprotein (LDL) cholesterol achieved. Atorvastatin, a newly licensed compound, reportedly lowers LDL with greater efficacy than other statins. The mechanism of this action was, therefore, explored in twenty patients with refractory familial hypercholesterolemia who received in a single-blind sequence simvastatin 40 mg/day, placebo and atorvastatin 10 mg/day each for 4 weeks. At the end of the placebo period the effects of single 40-mg doses of simvastatin and atorvastatin on plasma levels and urinary excretion of mevalonic acid, indices of HMG-CoA reductase activity, were compared. Administration of atorvastatin 10 mg daily for 1 month lowered LDL cholesterol by 32.5%, compared with placebo (P = 0.0001), which was 4.5% less than the decrease after simvastatin 40 mg daily (P = 0.33). The area under the plasma curve and urinary mevalonic acid/ creatinine ratio were both significantly less during the 24 h after a single dose of atorvastatin 40 mg than after a single dose of simvastatin 40 mg (P < 0.01). These findings suggest that the greater efficacy of atorvastatin compared with simvastatin is due to more prolonged inhibition of HMG-CoA reductase, presumably reflecting longer residence of atorvastatin or its active metabolites in the liver.
authors.affiliation: Clinical Sciences Centre, Royal Postgraduate Medical School, Hammersmith Hospital, London, United Kingdom.
authors.forename: R P
authors.initials: RP
authors.lastname: Naoumova
authors.forename: S
authors.initials: S
authors.lastname: Dunn
authors.forename: L
authors.initials: L
authors.lastname: Rallidis
authors.forename: O
authors.initials: O
authors.lastname: Abu-Muhana
authors.forename: C
authors.initials: C
authors.lastname: Neuwirth
authors.forename: N B
authors.initials: NB
authors.lastname: Rendell
authors.forename: G W
authors.initials: GW
authors.lastname: Taylor
authors.forename: G R
authors.initials: GR
authors.lastname: Thompson
mesh_terms: D000924:Anticholesteremic Agents / Q000494:pharmacology*; D000069059:Atorvastatin; D002784:Cholesterol / Q000096:biosynthesis*; D008078:Cholesterol, LDL / Q000097:blood; D003404:Creatinine / Q000652:urine; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005260:Female; D006538:Heptanoic Acids / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D006938:Hyperlipoproteinemia Type II / Q000188:drug therapy; D008297:Male; D008798:Mevalonic Acid / Q000097:blood / Q000652:urine; D008875:Middle Aged; D011758:Pyrroles / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D000924:Anticholesteremic Agents; D008078:Cholesterol, LDL; D004791:Enzyme Inhibitors; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D002784:Cholesterol; D000069059:Atorvastatin; D003404:Creatinine; D008798:Mevalonic Acid